| TITLE |
DATE |
| Emergent BioSolutions Announces Acceptance of Four TRU-016 Abstracts for Presentation at 2011 American Society of Hematology Annual Meeting |
5-Dec-2011 |
| Emergent BioSolutions Receives Orphan Drug Designation for Its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia |
1-Dec-2011 |
| Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a
Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis |
17-Nov-2011 |
| Emergent BioSolutions Reports Financial Results for Third Quarter and
First Nine Months of 2011 |
3-Nov-2011 |
| Emergent BioSolutions to Participate in November 2011 Investor
Conferences |
2-Nov-2011 |
| Emergent BioSolutions to Release Third Quarter 2011 Financial Results
and Conduct a Conference Call on November 3, 2011 |
20-Oct-2011 |
| Emergent BioSolutions Receives Award to Supply 44.75 Million Doses of
BioThrax to U.S. Government over Five Years |
3-Oct-2011 |
| Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare
Conference in London |
14-Sep-2011 |
| Emergent BioSolutions Co-Hosts Biopreparedness Conference with the
French High Committee for Civil Defense |
9-Sep-2011 |
| Results of Emergent BioSolutions Phase 1a Study on Adjuvanted
BioThrax Anthrax Vaccine Published in the Journal Vaccine |
26-Aug-2011 |
| Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in
Combination with Rituximab and Bendamustine in Subjects with Relapsed -
Indolent Lymphoma |
17-Aug-2011 |
| New Tuberculosis Vaccine Enters Phase IIb Proof-of-Concept Trial in
People Living with HIV in Senegal and South Africa |
11-Aug-2011 |
| Emergent BioSolutions to Present at Wedbush 2011 Life Sciences
Conference |
9-Aug-2011 |
| Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2011 |
4-Aug-2011 |
| Emergent BioSolutions to Release Second Quarter 2011 Financial Results and Conduct a Conference Call on August 4, 2011 |
11-Jul-2011 |
| Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax |
23-Jun-2011 |
| Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors |
13-Jun-2011 |
| Emergent BioSolutions' Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation |
9-Jun-2011 |
| Emergent BioSolutions Acquires Late-Stage Monoclonal Antibody Cancer Therapy from TenX BioPharma |
6-Jun-2011 |
| Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule |
31-May-2011 |
| U.S. Government Issues Request for Proposal for the Supply of 44.75
Million Doses of BioThrax over Next 5 Years |
26-May-2011 |
| Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference |
25-May-2011 |
| Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2011 at 10:00 am Eastern; Webcast Will Be Available |
17-May-2011 |
| Emergent BioSolutions Reports Financial Results for First Quarter 2011 |
5-May-2011 |
| U.S. Government Expands BioThrax Procurement Contract to 17.92M Doses from 14.5M Increasing Contract Value by up to $101 Million |
2-May-2011 |
| Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in
Phase IIb Clinical Trial |
28-Apr-2011 |
| Emergent BioSolutions to Release First Quarter 2011 Financial Results and Conduct a Conference Call on May 5, 2011 |
14-Apr-2011 |
| Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress |
12-Apr-2011 |
| Emergent BioSolutions Observes World TB Day |
24-Mar-2011 |
| Emergent BioSolutions to Present at Needham & Company Healthcare
Conference |
22-Mar-2011 |
| Emergent BioSolutions Reports Financial Results for Full Year 2010 |
10-Mar-2011 |
| Delegates from European Parliament Express Support for Rapid Development of New TB Vaccine |
25-Feb-2011 |
| Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10, 2011 |
24-Feb-2011 |
| Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic Leukemia |
25-Jan-2011 |
| Emergent BioSolutions Provides Preliminary 2010 Financial Results and Guidance for 2011 |
10-Jan-2011 |
| Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine |
27-Dec-2010 |
| Emergent BioSolutions to Webcast Presentation at JPMorgan Healthcare
Conference |
8-Dec-2010 |
| Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting |
6-Dec-2010 |
| Emergent BioSolutions Awarded Five Therapeutic Discovery Project Grants |
9-Nov-2010 |
| Emergent BioSolutions Announces Acceptance of TRU-016 and TRU-Adhance Abstracts for Presentation at American Society of Hematology Meeting |
9-Nov-2010 |
| Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences |
8-Nov-2010 |
| Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2010 |
4-Nov-2010 |
| Emergent BioSolutions Receives Orphan Drug Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalation Anthrax |
4-Nov-2010 |
| Emergent BioSolutions Receives Loan Repayment from Protein Sciences Corporation |
3-Nov-2010 |
| Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals |
28-Oct-2010 |
| Emergent BioSolutions to Release Third Quarter 2010 Financial Results
and Conduct a Conference Call on November 4, 2010 |
13-Oct-2010 |
| Emergent BioSolutions Launches Singapore Operations |
8-Oct-2010 |
| Emergent BioSolutions Receives Fast Track Designation for Its
Investigational Monoclonal Antibody for the Treatment of Inhalational
Anthrax |
1-Oct-2010 |
| Emergent BioSolutions to Participate in October 2010 Investor
Conferences |
27-Sep-2010 |
| Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6
Million to Develop rPA Anthrax Vaccine |
17-Sep-2010 |
| Emergent BioSolutions Announces Early Termination of HSR Waiting
Period for Its Acquisition of Trubion Pharmaceuticals |
8-Sep-2010 |
| Emergent BioSolutions Announces Commencement of Phase I Clinical Trial for Monoclonal Antibody to Treat Inhalational Anthrax |
8-Sep-2010 |
| Emergent BioSolutions Awarded NIAID Contract That Increases Potential
Funding to Over $58 Million for Advanced Development of Third Generation
Anthrax Vaccine |
1-Sep-2010 |
| Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars |
24-Aug-2010 |
| Emergent BioSolutions Announces Appointment of John E. Niederhuber,
M.D. to the Company's Board of Directors |
24-Aug-2010 |
| Emergent BioSolutions to Acquire Trubion Pharmaceuticals |
12-Aug-2010 |
| Emergent BioSolutions and Temasek Life Sciences Ventures Establish
Joint Venture to Develop Broad Spectrum Pandemic Flu Vaccine and
Therapeutic |
11-Aug-2010 |
| Emergent BioSolutions Reports Financial Results for Second Quarter
and First Six Months of 2010 |
5-Aug-2010 |
| Emergent Revises Upward 2010 Financial Forecast |
20-Jul-2010 |
| Maryland Governor Martin O'Malley Leads Ribbon Cutting Ceremony at
Emergent's Baltimore Manufacturing Facility |
16-Jul-2010 |
| Emergent BioSolutions Awarded HHS Contract Valued at Up to $107
Million to Develop Large-Scale Manufacturing for BioThrax |
14-Jul-2010 |
| Emergent BioSolutions to Release Second Quarter 2010 Financial
Results and Conduct a Conference Call on August 5, 2010 |
13-Jul-2010 |
| Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO
Parliamentarians |
12-Jul-2010 |
| Emergent BioSolutions Completes Deliveries of BioThrax to Allied
Foreign Governments |
24-Jun-2010 |
| Emergent BioSolutions Announces Appointment of Marvin White to the
Company's Board of Directors |
4-Jun-2010 |
| Emergent BioSolutions to Participate in June 2010 Investor Conferences |
1-Jun-2010 |
| Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday
May 20, 2010 at 10:00 am Eastern; Webcast Will Be Available |
19-May-2010 |
| Emergent BioSolutions IND for Anthrax Monoclonal Antibody Therapeutic
Clears FDA Review |
17-May-2010 |
| Emergent BioSolutions Recognized as Biotechnology Firm of the Year by
Tech Council of Maryland |
13-May-2010 |
| Emergent BioSolutions Hosts Biopreparedness Forum for Members of the
NATO Parliamentary Assembly |
6-May-2010 |
| Emergent BioSolutions Reports Financial Results for First Quarter 2010 |
5-May-2010 |
| Emergent BioSolutions to Participate on Vaccine Panel at BIO
International Convention 2010 |
3-May-2010 |
| Emergent BioSolutions to Release First Quarter 2010 Financial Results
and Conduct a Conference Call on May 5, 2010 |
21-Apr-2010 |
| Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as
Outstanding International Business Leader |
11-Mar-2010 |
| Emergent BioSolutions Reports Financial Results for Full Year 2009 |
4-Mar-2010 |
| Emergent BioSolutions to Participate in March 2010 Investor Conferences |
22-Feb-2010 |
| Emergent BioSolutions to Release Fourth Quarter and Full Year 2009 Financial Results and Conduct a Conference Call on March 4, 2010 |
25-Jan-2010 |
| Emergent BioSolutions Announces R. Don Elsey, Chief Financial Officer, to Join Board of Directors of MdBio Foundation |
11-Jan-2010 |
| Emergent BioSolutions Provides Preliminary 2009 Financial Results and Guidance for 2010 |
11-Jan-2010 |
| HHS Cancels RFP for rPA Procurement and Modifies Their Approach in Favor of BAA for Development of rPA Vaccines |
7-Dec-2009 |
| Former U.K. Health Protection Agency Director Rejoins Emergent BioSolutions to Head Biodefense Business |
1-Dec-2009 |
| Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences |
30-Nov-2009 |
| Emergent BioSolutions Enhances Manufacturing Infrastructure with Strategic Acquisition in Baltimore |
13-Nov-2009 |
| Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2009 |
5-Nov-2009 |
| Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences |
2-Nov-2009 |
| Emergent BioSolutions Sponsors Security and Defence Agenda Roundtable on Biopreparedness |
14-Oct-2009 |
| Emergent BioSolutions to Release Third Quarter 2009 Financial Results and Conduct a Conference Call on November 5, 2009 |
8-Oct-2009 |
| NIAID to Fund Development of Emergent BioSolutions' Advanced Anthrax Vaccine Candidate |
30-Sep-2009 |
| Emergent BioSolutions Issues Statement on Court Ruling |
14-Sep-2009 |
| Emergent BioSolutions to Webcast Presentation at Upcoming Investor Conference |
4-Sep-2009 |
| Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2009 |
6-Aug-2009 |
| Emergent BioSolutions Expands Manufacturing and Development Infrastructure Through a Series of Real Estate Transactions |
6-Aug-2009 |
| Emergent BioSolutions to Release Second Quarter 2009 Financial Results and Conduct a Conference Call on August 6, 2009 |
21-Jul-2009 |
| Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Winner in Greater Washington |
18-Jun-2009 |
| Emergent BioSolutions Chief Financial Officer, Don Elsey, Named SmartCFO of the Year |
15-Jun-2009 |
| Emergent BioSolutions Meets With FDA To Review Regulatory Strategy for Recombinant Anthrax Vaccine |
11-Jun-2009 |
| Emergent BioSolutions Receives FDA Approval Extending Shelf Life of BioThrax (Anthrax Vaccine Adsorbed) to 4 Years |
10-Jun-2009 |
| Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences |
26-May-2009 |
| Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday, May 21, 2009 at 10:00 am Eastern |
19-May-2009 |
| Emergent BioSolutions Submits to FDA Development Plan Required of Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract with HHS |
13-May-2009 |
| Emergent BioSolutions Launches BioThrax.com, an Educational Website about BioThrax (Anthrax Vaccine Adsorbed) and Anthrax Disease |
8-May-2009 |
| Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist in Greater Washington |
8-May-2009 |
| Emergent BioSolutions Reports Financial Results for First Quarter 2009 |
7-May-2009 |
| Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement with Vivalis to Explore Production Of MVA85A TB Vaccine Candidate Using EB66(R) Cell Line |
5-May-2009 |
| Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement With ProBioGen To Explore Production Of MVA85A TB Vaccine Candidate Using AGE1.CR.pIX(R) Cell Line |
5-May-2009 |
| HHS Extends Deadline for Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract to Submit Development Plan to FDA for Review to June 15, 2009 |
22-Apr-2009 |
| New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa |
22-Apr-2009 |
| Emergent BioSolutions to Release First Quarter 2009 Financial Results and Conduct a Conference Call on May 7, 2009 |
21-Apr-2009 |
| HHS Requires Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract to Submit Development Plan to FDA for Review |
16-Apr-2009 |
| Emergent BioSolutions Announces Commencement of Phase I/II Clinical Trial of Anthrax Immune Globulin for Treating Anthrax Disease |
17-Mar-2009 |
| Emergent BioSolutions Reports Financial Results for Full Year 2008 |
5-Mar-2009 |
| Emergent BioSolutions to Webcast Presentation at the Cowen & Co. 29th Annual Health Care Conference on Tuesday, March 17, 2009 |
27-Feb-2009 |
| Emergent BioSolutions Announces That BioThrax (Anthrax Vaccine Adsorbed) Receives Market Authorization in India |
12-Feb-2009 |
| Emergent BioSolutions to Release Full Year 2008 Financial Results and Conduct a Conference Call on March 5, 2009 |
5-Feb-2009 |
| Emergent BioSolutions Provides Preliminary 2008 Financial Results and Guidance for 2009 |
9-Jan-2009 |
| Emergent BioSolutions Recognized by Security Magazine Among Best Security Organizations |
8-Jan-2009 |
| Emergent BioSolutions Ends Efforts to Acquire Protein Sciences |
6-Jan-2009 |
| Emergent BioSolutions Receives FDA Approval for BioThrax Supplemental Biologics License Application |
19-Dec-2008 |
| Emergent BioSolutions to Webcast Presentation at the J.P. Morgan 27th Annual Healthcare Conference on Wednesday, January 14, 2009 |
8-Dec-2008 |
| Emergent BioSolutions to Webcast Presentation at the 6th Annual Southwestern Showcase Investor Conference on November 20, 2008 |
18-Nov-2008 |
| Emergent BioSolutions Files Universal Shelf Registration Statement |
12-Nov-2008 |
| Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2008 |
6-Nov-2008 |
| Emergent BioSolutions to Webcast Presentation at the Rodman & Renshaw Annual Global Investment Conference on November 12, 2008 |
31-Oct-2008 |
| Emergent BioSolutions to Release Third Quarter 2008 Financial Results and Conduct a Conference Call on November 6, 2008 |
16-Oct-2008 |
| U.S. Government Issues Declaration Covering Emergent BioSolutions' BioThrax(R) and Anthrax Immune Globulin under Prep Act |
9-Oct-2008 |
| U.S. Government to Purchase Additional 14.5 Million Doses of BioThrax under New Contract Valued at up to $404 Million |
1-Oct-2008 |
| Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine |
26-Sep-2008 |
| Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range |
12-Sep-2008 |
| Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continued Development of Anthrax Monoclonal Antibody |
3-Sep-2008 |
| Emergent BioSolutions Reports Financial Results for Second Quarter 2008 |
7-Aug-2008 |
| Emergent BioSolutions to Present at the BMO Capital Markets Focus on Healthcare Conference on August 6, 2008 |
5-Aug-2008 |
| Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine |
31-Jul-2008 |
| Statement by Emergent BioSolutions in Response to Attempt by Protein Sciences Corporation to Terminate Asset Purchase Transaction |
29-Jul-2008 |
| Emergent BioSolutions to Release Second Quarter 2008 Financial Results and Conduct a Conference Call on August 7, 2008 |
25-Jul-2008 |
| Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of the Company's Recombinant Botulinum Vaccine (rBOT) and Next Generation Anthrax Vaccine (NGAV) Candidates |
24-Jul-2008 |
| Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vaccine with Funding from Wellcome Trust and Aeras Global TB Vaccine Foundation |
23-Jul-2008 |
| Emergent BioSolutions Initiates Lawsuit Against Protein Sciences and Its Senior Management Regarding Delayed Asset Acquisition |
9-Jul-2008 |
| Emergent BioSolutions and the European Corporate Security Association (ECSA) Sponsor a Conference on Bioterrorism |
5-Jun-2008 |
| Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate |
5-Jun-2008 |
| Emergent BioSolutions to Webcast Presentation at the Jefferies and Company 2nd Annual Healthcare Conference on June 25, 2008 |
4-Jun-2008 |
| Emergent BioSolutions to Acquire Protein Sciences' Phase III Recombinant Flu Vaccine Candidate, FluBlok(R), and Related Novel Platform Technology |
27-May-2008 |
| Emergent BioSolutions Reports Financial Results for First Quarter 2008 |
7-May-2008 |
| Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate and Technology |
5-May-2008 |
| Emergent BioSolutions to Release First Quarter 2008 Financial Results and Conduct a Conference Call On May 7, 2008 |
10-Apr-2008 |
| Emergent BioSolutions to Hold Annual Meeting of Stockholders Wednesday, May 21, 2008 at 10:00 am Eastern |
8-Apr-2008 |
| Emergent BioSolutions to Present at the Cowen and Company 28th Annual Health Care Conference on March 18, 2008 |
10-Mar-2008 |
| Emergent BioSolutions Reports Financial Results for 2007 |
7-Mar-2008 |
| Emergent BioSolutions Acquires Monoclonal Anthrax Product Candidate |
6-Mar-2008 |
| Emergent BioSolutions Appoints Dr. W. James Jackson as Chief Scientific Officer |
3-Mar-2008 |
| Emergent BioSolutions to Release Full Year 2007 Financial Results and Conduct a Conference Call on March 7, 2008 |
25-Feb-2008 |
| Emergent BioSolutions to Present at BIO CEO & Investor Conference on February 11, 2008 |
7-Feb-2008 |
| Emergent BioSolutions and Ninebio Sdn. Bhd. Announce Joint Venture in Malaysia |
24-Jan-2008 |
| Safety Monitoring Committee Recommends That Emergent BioSolutions Continue Its Hepatitis B Immunotherapy Phase II Trial |
9-Jan-2008 |
| Emergent BioSolutions Announces That the Final Phase II Clinical Study Results for Typhoid Vaccine Reaffirms Clinical Endpoints Met; Immune Response Seen in 97% of Treated Subjects |
8-Jan-2008 |
| Emergent BioSolutions Announces Better-Than-Expected Preliminary 2007 Financial Results and Provides 2008 Guidance |
7-Jan-2008 |
| Emergent BioSolutions to Present at Upcoming Investor Conferences |
10-Dec-2007 |
| U.S. Department of Health and Human Services Remains Committed to Procurement of BioThrax(R) Under Current Contract |
19-Nov-2007 |
| Emergent BioSolutions to Lead a United States Delegation to the United States - India Business Council (a Subsidiary of the US Chamber of Commerce) Health Summit in India |
12-Nov-2007 |
| Emergent BioSolutions Announces Update on Department of Defense Procurement Strategy For BioThrax(R) (Anthrax Vaccine Adsorbed) |
8-Nov-2007 |
| Emergent BioSolutions Completes Clinical Study in Support of a Post-Exposure Prophylaxis Indication for BioThrax(R) (Anthrax Vaccine Adsorbed) |
5-Nov-2007 |
| Emergent BioSolutions Reports Financial Results for Third Quarter 2007 |
2-Nov-2007 |
| Emergent BioSolutions to Present at November Investor Conferences |
29-Oct-2007 |
| Emergent BioSolutions to Release Third Quarter 2007 Financial Results on November 2, 2007; Management Will Conduct a Conference Call to Discuss Results as Well as Provide an Update on Business Developments |
22-Oct-2007 |
| Emergent BioSolutions Announces Dr. Stephen Lockhart Joins Company to Lead Commercial Product Development Subsidiary |
18-Oct-2007 |
| Emergent BioSolutions' Typhoid Vaccine Candidate Achieves Endpoints in Phase II Clinical Study |
10-Oct-2007 |
| Emergent BioSolutions Announces the Appointment of Denise Landry as Senior Vice President, Quality |
9-Oct-2007 |
| Emergent BioSolutions to Present at BIO InvestorForum 2007 |
3-Oct-2007 |
| Emergent BioSolutions Completes First Delivery of BioThrax(R) (Anthrax Vaccine Adsorbed) to The Department of Health and Human Services under New Contract |
2-Oct-2007 |
| Emergent BioSolutions Receives Development Contract from NIAID/BARDA to Fund Continued Development of Anthrax Therapeutic |
27-Sep-2007 |
| Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services |
26-Sep-2007 |
| Emergent BioSolutions to Present at the Thomas Weisel Partners Healthcare Conference 2007 |
20-Aug-2007 |
| Emergent BioSolutions Reports Financial Results for Second Quarter 2007 |
6-Aug-2007 |
| Emergent BioSolutions to Release Second Quarter 2007 Financial Results on August 6, 2007; Management Will Conduct a Conference Call to Discuss Results as Well as Provide an Update on Business Developments |
20-Jul-2007 |
| Emergent BioSolutions and HSBC Sign $30 Million Loan to Support Manufacturing Expansion Program |
3-Jul-2007 |
| Emergent BioSolutions Anticipates 2nd Quarter BioThrax Revenues of Approximately $20 Million Based on Accelerated Delivery to Department of Defense |
27-Jun-2007 |
| Emergent BioSolutions to Present at the Jefferies & Company Healthcare Conference |
20-Jun-2007 |
| Emergent BioSolutions Announces Expansion of Board of Directors and Appointment of Dr. Sue Bailey to the Company's Board of Directors |
15-Jun-2007 |
| Emergent BioSolutions Announces Results from Annual Meeting of Stockholders |
14-Jun-2007 |
| Emergent BioSolutions to Hold Annual Meeting of Stockholders |
11-Jun-2007 |
| Emergent BioSolutions to Present at Morgan Keegan Homeland Security Technology Conference 2007 |
18-May-2007 |
| Emergent BioSolutions Announces Management Changes |
16-May-2007 |
| Emergent BioSolutions Reports Financial Results for First Quarter 2007 |
9-May-2007 |
| Emergent BioSolutions to Present at The Rodman and Renshaw 4th Annual Global Healthcare Conference |
1-May-2007 |
| Emergent BioSolutions to Release First Quarter 2007 Financial Results on May 9, 2007 |
25-Apr-2007 |
| Emergent BioSolutions Announces That Department of Health and Human Services and Department of Defense Issued Notices of Intent to Procure up to a Combined 22.75 Million Doses of BioThrax(R)(Anthrax Vaccine Adsorbed) |
18-Apr-2007 |
| CORRECTING and REPLACING Emergent BioSolutions Reports Financial Results for 2006 |
22-Mar-2007 |
| Emergent BioSolutions Announces Management Promotions |
22-Mar-2007 |
| Emergent BioSolutions Reports Financial Results for 2006 |
22-Mar-2007 |
| Emergent BioSolutions Files Investigational New Drug Application With FDA for Pivotal Anthrax Immune Globulin Clinical Trial |
21-Mar-2007 |
| Emergent BioSolutions Gains Rights To VaxImmune(TM) From Coley Pharmaceutical Group to Expand Its Anthrax Franchise |
15-Mar-2007 |
| Emergent BioSolutions to Host Conference Call on March 22, 2007 to Announce Fourth Quarter and Full Year 2006 Financial Results |
15-Mar-2007 |
| Emergent BioSolutions to Present at the Cowen & Company 27th Annual Health Care Conference |
5-Mar-2007 |
| Emergent BioSolutions Delivers Approximately 1 Million Doses of BioThrax(R) Ahead of Schedule to U.S. Department of Health and Human Services for Strategic National Stockpile |
23-Feb-2007 |
| Emergent BioSolutions Remains Committed to Development of Enhanced Anthrax Countermeasures |
22-Feb-2007 |
| FDA Grants Fast Track Designation to Emergent BioSolutions' BioThrax(R) for Post-Exposure Prophylaxis against Anthrax Infection |
12-Feb-2007 |
| Emergent BioSolutions to Present at BIO CEO & Investor Conference |
30-Jan-2007 |
| Emergent BioSolutions Announces Expected 2006 Total Revenue of Approximately $150 Million |
8-Jan-2007 |
| Emergent BioSolutions to Present at JPMorgan Healthcare Conference |
21-Dec-2006 |
| National Institutes of Health to Sponsor Clinical Trial for Emergent BioSolutions' Group B Streptococcus Vaccine Candidate |
21-Dec-2006 |
| Emergent BioSolutions Applauds Passage and Signing of BARDA Legislation |
20-Dec-2006 |
| Emergent BioSolutions Delivers over 3 Million Doses of BioThrax(R) to U.S. Department of Health and Human Services for Strategic National Stockpile |
14-Dec-2006 |
| Emergent BioSolutions Celebrates Initial Public Offering; CEO To Ring Opening Bell on the NYSE |
21-Nov-2006 |
| Emergent BioSolutions Announces Pricing of Its Initial Public Offering |
15-Nov-2006 |
| Emergent BioSolutions Awarded Two Grants From NIAID To Support Development Of Anthrax Immune Globulin Therapeutic |
31-Aug-2006 |
| U.S. Department Of Homeland Security Certifies BioThrax® (Anthrax Vaccine Adsorbed) As An Approved Product For Homeland Security |
29-Aug-2006 |
| Emergent BioSolutions Inc. Files Registration Statement For Proposed Initial Public Offering |
15-Aug-2006 |
| Emergent BioSolutions Expands Presence In Germany |
3-Aug-2006 |
| Cornerstone Ceremony Welcomes New Vaccine Production Facility To Michigan |
21-Jul-2006 |
| Joe M. Allbaugh, Former FEMA Director, Joins Emergent BioSolutions' Board Of Directors |
12-Jul-2006 |
| Former DHHS Secretary, Dr. Louis W. Sullivan, Joins Board Of Directors Of Emergent BioSolutions |
21-Jun-2006 |
| Emergent BioSolutions Signs Agreement with sanofi pasteur for Development of Novel Meningitis B Vaccine |
5-Jun-2006 |
| DHHS Expands Emergent BioSolutions' Contract To Supply BioThrax To The Strategic National Stockpile |
5-May-2006 |
| Emergent BioSolutions Announces Investments In Manufacturing Capability |
14-Feb-2006 |
| New Studies Conclude BioThrax Plus Antibiotics Provide 100% Protection In Animals When Administered After Anthrax Exposure |
10-Jan-2006 |
 |
